[ad_1]
GlaxoSmithKline and Pfizer are waiting to raise £ 60bn in funding for medical treatment, encouraged by opponents. Unilever donates £ 50bn.
GSK rejected Unilever’s request on Saturday as “unsuccessful”, as it did show good business acumen.
Giving 25 percent to the estimated business value – which could cost more than $ 60bn – would require considerable consideration from the board, according to one person close to Pfizer. Someone familiar with the matter said “it would be difficult to deny”.
GSK was planning to change the session, which owns 68 percent, but has been forced to consider trading, including in the US hedge fund Elliott Management.
Marco Taricco, chief investment officer at Bluebell Capital Partners, a businessman who encouraged GSK to focus on sales, said: . ”
Richard Buxton of Jupiter Capital Management, a 30-year-old holder at GSK, said the company needs to continue because the consumer health sector has “a bright future as an independent company that can reform over time as the market understands. It’s good.”
“The idea of allowing Unilever terrorists to work is ridiculous… There is no price I would like to sell them for,” he said.
The two sides are at odds with the value of the consumer companies and have different opinions on the price already offered, depending on people who are well aware of what is going on.
The GSK’s target of 4 to 6 percent of medium-term growth is higher than most experts calculate about 3 to 4 percent, which could lead them to increase their current estimates from the current £ 37bn to £ 48bn.
Unilever’s move could encourage more applicants to come, said people who briefly briefed them on the matter. Procter & Gamble has been considering adding more consumer health products to its products, he said. But it did not provide an opportunity and in the end it could decide to transfer Johnson & Johnson’s assets, which the US company decided to abandon in November.
Competitive competition in the GSK / Pfizer business may be based on pre-interest rates, interest rates, lower prices and refunds for high-income young people, a potential contract of 14 to 15 percent and a minimum of 25 percent, according to an expert consultant. ake.
Consumer Ebitda is expected to hit $ 2.7bn in 2022, so its price will be around £ 48.6bn to £ 51.3bn. The £ 9.6bn joint venture could also add £ 1.3bn to £ 1.4bn. The fee may be at least £ 12bn, making a purchase price of £ 61.5bn.
But the GSK team should also try other things, including tax and time. A former committee member stated that one of the most recent campaigns was that they should be tax-free. The sale could mean that GSK and its shareholders have had a tax bill, although there may be ways to reduce this.
“I suspect GSK wants to be diverted from demerger,” he said.
The change was planned in mid-2022 but selling this scale would take a long time. Supervisors can also monitor the situation even though there is no significant interaction between the two companies.
Unilever may struggle to raise the price too high, with the risk that it could be left out of debt. Bruno Monteyne, a Bernstein researcher, said: “Unilever already has a lot of money, and by paying a lot of money, you can have a new company that will look at years of debt repayment instead of encouraging growth.”
Jefferies analyst Martin Deboo has warned that a total of £ 55bn will bring up a five-term debt withholding.
[ad_2]
Source link
